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vealed within 2 days after injury. At 21 days, healing of the arterial 
injury in WT mice was associated with formation of neointima that 
consisted predominantly of anti-alpha actin immunoreactive SMCs 
and of a minor population (5% to 10%) of anti-CD45 immunore- 
active inflammatory cells. Neointima first appeared at the borders of 
the injury (presumably due to proliferation and migration of viable 
SMCs across the internal elastical membrane) and progressed 
towards the necrotic enter (presumably due to migration of medial 
and neointimal SMCs). In contrast to the electric injury model, 
guidewire injury did not deplete the media of all viable SMCs and 
(presumably as a result of proliferation and migration of medial 
SMCs across the internal elastical membrane) induced uniform 
neointima formation over the entire length of the injury. 
Comparative morphometric analysis revealed that deficiency of 
t-PA or u-EAR does not affect the degree or rate of neointima 
formation, but that deficiency ofPAI- 1 significantiy accelerates and 
that deficiency ofu-PA, Plg, or the combined eficiency oft-PA and 
u-PA greatly reduces and delays neointima formation and neointi- 
mal accumulation fsmooth muscle cells.2° Furthermore, progres- 
sion ofneointima from the uninjured borders into the center of the 
electrically injured region (which is depleted of viable smooth 
muscle cells by the electrical injury) occurred at an increased rate in 
PAl-l-deficient compared with u-PA-deficient arteries. These 
results were extended by adenovirus-mediated PAl-1 gene transfer 
in PAl-1 deficient mice after vascular injury, which induced plasma 
PAl-1 levels 100- to 1000-fold above WT and inhibited neointima 
formation to the same extent as observed in u-PA-deficient mice. 
The same genotype-related differences as observed in the electrical 
injury model namely, reduced neointima formation in u-PA-de- 
ficient mice and increased neointima formation in PAl- 1 deficient 
mice--were observed after mechanical injury. Because cellular 
proliferation was similar in all genotypes, u-PA appears to promote 
neointima formation by facilitating cellular migration rather than 
proliferation. Our data suggest that n-PA rather than t-PA contrib- 
utes to vascular wound healing and neointima formation in mice. 
Further study is required to elucidate whether other mechanisms, 
including apoptosis or matrix remodeling, are affected by these 
genetic manipulations, assuggested by our previous observations 
of impaired degradation of 3H-proline-labeled subendothelial 
matrix by u-PA-deficient but not by t-PA-deficient macrophages) 7 
It is possible that u-PA-facilitated cellular migration isinvolved not 
only in neointima formation, as demonstrated in the present study, 
but also in other processes of vascular emodeling, such as after 
transplantation, during hypertension, atherosclerosis, or aneurysm 
formation. Appropriate local control ofu-PA activity after vascular 
trauma might constitute a new therapeutic approach to arterial 
neointima formation after coronary angioplasty. 
Peter Carmelie~, MD, PhD 
Katholieke Uni~ersiteit Leuven 
Leu~en, Belgium 
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ARTERIAL RESPONSE TO INJURY IN 
THE MOUSE 
We have used animal models to determine what factors may be 
important in the growth of arterial esions. This approach as 
allowed us to identify the role of growth factors and how they relate 
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to the proliferation of SMCs in balloon-injured arteries. These 
studies for the most part relied on the use of specific antibodies and 
of purified recombinant proteins. An alternative to this approach is
to use animals with gene deletions, and because of the availability of 
knock-outs mice, we have developed a model of arterial injury in 
this species. The advantages of this system are apparent in that no 
inhibitor is required and inhibition is absolute, but as will be 
discussed in this meeting, functional redundancy of a gene can 
cause problems that are not readily resolved without further 
experimental procedures. 
We decided to transfer the system of experimental rterial 
injury to the mouse so as to study the importance ofgene deletion 
in the development of SMC-rich arterial esions. Mice carotid 
arteries were chosen for this study because the), are readily 
accessible and, as in the rat, we would be able to study the response 
of both the endothelial cell and smooth muscle growth to injury in 
the same artery. A loop of 6 /0  monofilament was used to denude 
the common carotid artery, and 2 weeks after surgery the carotid 
artery is completely covered with new endothelial cells and an 
intimal lesion comprising SMCs is formed. These lesions varied 
from those induced in rat arteries in that the SMC replication rate 
was relatively low and the size of the intimal lesions varied 
considerably. After 2 weeks the number ofintimal cell layers in the 
lesion could vary from one cell to approximately five cells thick. 
Around this time the regrowth of endothelium was complete, and 
the lesion became quiescent. This occurrence has diminished the 
usefulness of this model in studying enes that are important for 
SMC proliferation because it is difficult to detect any reduction in 
lesion size when the intima is only one ceil thick. The outgrowth of 
endothelium, however, is more reproducible, and we have exam- 
ined the role of particular genes that are considered to be important 
for its regrowth. 
In vitro data suggests that the plasminogen activators, and 
particularly urokinase-like plasminogen activator (uPA), play an 
important role in the growth of endothelial cells. Regenerating 
endothelial cells express uPA, and their growth into a wound can be 
stopped with plasmin inhibitors. These regenerating cells also 
express the uroldnase-like plasminogen activator receptor (uPAR). 
A similar pattern of  gene expression was observed in denuded rat 
arteries in that by in situ hybridization both tPA and uPA were 
strongly expressed by those endothelial cells at the wound edge but 
not in control arteries nor in cells at some distance from the wound. 
The uPA receptor was likewise expressed by those endothelial cells 
adjacent o the wound. At later times after injury when the 
endothelium had become quiescent, no expression of tPA, uPA, 
and uPAR was detected in cells either adjacent to the wound or at 
other sites. This pattern of plasminogen activators and their 
receptor strongly support he hypothesis that plasmin generation is 
important for endothelial cell regrowth. 
In a subsequent experiment we used the plasmin inhibitor 
tranexamic acid to test if it would block endothelial cell prolifera- 
tion. Even though in this study we achieved a significant inhibition 
in the migration rate of SMC, we were not able to effect he rate of 
endothelial cell proliferation. As with any inhibitor study, a negative 
result is not conclusive, and therefore the study was repeated on 
mice in which the uPAR gene was deleted, thereby blocldng the 
uPA activation of plasminogen. In such mice, endothelial cell 
regrowth was assessed in the carotid arteries after total denudation. 
Eight days after injury, endothelial cell outgrowth was 1.09 _+ 0.26 
in the uPAR knock-outs and 1.95 + 0.81 in the controi arteries 
( p = 0.007). By 12 days after injury, outgrowth was 2.72 _+ 0.62 in 
the uPAR knock-outs and 3.23 -+ 1.28 in the control arteries. No 
difference was observed in the size of the intimal esions at both 
times. These data suggest hat uPAR and presumably uPA are 
important for the regrowth of endothelium in large arteries, but 
alternative mechanisms such as tPA induced activation of plas- 
minogen can compensate. 
Recent data has shown that matrix metalloproteinases (MMI's) 
are important for the migration of SMCs from the media to the 
intima. MMPs have the ability to degrade a variety of matrix 
molecules found in the arteriaI wall, and recently we have detected 
two gelatinases, MMP2 and MMPg, in rat injured arteries. Within 
6 hours after balloon injury, a significant increase in mRNA of an 
88 kD gelatinase (MMP9) is observed, and remains elevated for 
approximately 6 days (4518). Expression of this MMP was not seen 
in the intima, nor was it correlated to smooth muscle ceil replica- 
tion. The transcript for 72 led gelatinase (MMP2) was present in 
normal arteries and showed little change after injury. The activity of 
MMP in balloon-injured rat arteries was assessed by zymography, 
and within 1 day an increase in 88 kD activity was observed. Both 
inactive and active MMP2 were observed in control arteries, but by 
day 4 a marked increase in active MMP2 was noted. We also noted 
that an inhibitor ofMMP, TIMP-2, is expressed inboth normal and 
injured arteries. Thus even though there is a correlation between 
expression of MMI'9 and activities of MMP9 and MMP2 with the 
migration of smooth muscle cells into the intima, it is still unclear 
whether MMI's are necessary for the growth of intimal lesions. 
Using a metalloprotease inhibitor, the migration of smooth muscle 
cells into the intima was blocked, and intimal lesion size was 
markedly reduced by day 10. By 14 days, however, the size of the 
lesions in control and treated arteries were the same despite the fact 
that the MMP inhibitor was administered through the entire 
experiment. The "catch-up" in the lesion size was accomplished by 
a prolonged increase in intimai cell replication. Currently, we are 
unsure as to the mechanism that controls this replication, but it 
appears that the inhibitor is not directly affecting the endothelial 
cells. Studies on the role of MMPs in lesion development are now 
underway using TIMP transgenic mice. 
In summary, the use of normal and transgenic mice are still 
invaluable to identify selected gene products that play a role in 
lesion growth, and these data have allowed us to make significant 
inroads in understanding how and why SMCs proliferate. That 
these data have not been helpful in controlling lesion growth in 
human beings perhaps reflects that mechanisms other than SMC 
replication are important, and only now are these processes being 
examined. 
Michael A. Reidy, PhD 
University of Washington 
Seattle, Wash. 
TRANSGENIC  RABBIT  MODELS 
OF ATHEROSCLEROSIS 
Transgenic rabbits have been developed to study the mechanisms 
by which perturbations in plasma lipid metabolism contribute to 
the development of atherosclerosis. We have generated and char- 
acterized several independent lines of transgenic rabbits that 
ovcrexpress human hepatic lipase, human apolipoprotein (apo) E, 
or human apoB. These animals are valuable new models for the 
investigation of the roles of these proteins in cardiovascular 
diseases. 
Rationale for developing transgenic rabbits 
For the investigation of vascular diseases, the choice of 
experimental nimal will have an impact on the effects of transgene 
expression and the interpretation fresults. Although mice are the 
most common animal model used for investigating transgene 
expression, they are relatively resistant to the effects of dietary 
